ERAS - Erasca receives FDA clearance to begin trial of non-small cell lung cancer treatment
- Erasca ( NASDAQ: ERAS ) said on Tuesday the United States Food and Drug Administration had cleared an investigational new drug ( IND ) application for its oral drug, ERAS-3490, to treat KRAS G12C-mutated solid tumors, including non-small cell lung cancer.
- ERAS-3490 has demonstrated robust anti-tumor activity and dose-dependent survival benefit in the KRAS G12C NSCLC intracranial model NCI-H1373-luc, a nonclinical model of NSCLC CNS metastases.
For further details see:
Erasca receives FDA clearance to begin trial of non-small cell lung cancer treatment